JonesResearch Starts Coverage on Atai Beckley & Mind Medicine with Buy Ratings
JonesResearch gives Buy ratings to Atai Beckley and Mind Medicine, highlighting potential in psychedelic drug development for depression and anxiety.
JonesResearch gives Buy ratings to Atai Beckley and Mind Medicine, highlighting potential in psychedelic drug development for depression and anxiety.
Berenberg maintains Buy rating on ATAI Life Sciences (ATAI) with $12 price target, citing exceptional progress, strong pipeline momentum, and upcoming Phase 3 trials for psychedelic treatments.
Jefferies raises Atai Life Sciences price target to $10 following FDA Breakthrough Therapy Designation for depression drug BPL-003, citing 72% approval rate for BTD drugs.
Needham initiates Atai Life Sciences with Buy rating and $12 target, projecting BPL-003 could capture 20% market share by 2035 with $2.5B+ in sales.